Onxeo has engaged MCT (Regional CRO specialized on Middle East and Africa) to expand “Relieve” phase III HCC study in 3 Middle East countries (Lebanon, Egypt and Saudi Arabia). More information in Onxeo press release: 150326EN_Livatag
Related Posts
Article published on Journal for Clinical studies regarding Egypt
News / January 11, 2016
COVID-19 Clinical Trials Across Africa
News / August 8, 2021